Browsing 1 studies for Stuart Cramer
AALL1732-A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
- Date Added
- December 6th, 2019
- PRO Number
- Pro00093700
- Researcher
-
Stuart Cramer
List of Studies